rs74205173
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 4P and 9B. PM1PM2BP4_StrongBP6BS1
The ENST00000307503.4(AGXT):āc.145A>Cā(p.Met49Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00016 in 1,596,674 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
ENST00000307503.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
AGXT | NM_000030.3 | c.145A>C | p.Met49Leu | missense_variant | 1/11 | ENST00000307503.4 | NP_000021.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
AGXT | ENST00000307503.4 | c.145A>C | p.Met49Leu | missense_variant | 1/11 | 1 | NM_000030.3 | ENSP00000302620 | P1 | |
AGXT | ENST00000472436.1 | n.165A>C | non_coding_transcript_exon_variant | 1/5 | 2 |
Frequencies
GnomAD3 genomes AF: 0.000302 AC: 44AN: 145688Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000498 AC: 122AN: 245148Hom.: 0 AF XY: 0.000390 AC XY: 52AN XY: 133408
GnomAD4 exome AF: 0.000146 AC: 212AN: 1450894Hom.: 0 Cov.: 34 AF XY: 0.000158 AC XY: 114AN XY: 721328
GnomAD4 genome AF: 0.000295 AC: 43AN: 145780Hom.: 0 Cov.: 33 AF XY: 0.000267 AC XY: 19AN XY: 71286
ClinVar
Submissions by phenotype
Primary hyperoxaluria, type I Uncertain:1Benign:3
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Jan 11, 2017 | - - |
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Oct 02, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign. - |
Likely benign, criteria provided, single submitter | curation | Clinical Biochemistry Laboratory, Health Services Laboratory | Oct 27, 2023 | ACMG:BS1 BP2 - |
Likely benign, no assertion criteria provided | clinical testing | Natera, Inc. | Jan 14, 2020 | - - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 24, 2021 | Variant summary: AGXT c.145A>C (p.Met49Leu) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.0005 in 275722 control chromosomes, predominantly at a frequency of 0.0065 within the East Asian subpopulation in the gnomAD database. The observed variant frequency within East Asian control individuals in the gnomAD database is approximately 2.74 fold of the estimated maximal expected allele frequency for a pathogenic variant in AGXT causing Primary Hyperoxaluria Type 1 phenotype (0.0024), strongly suggesting that the variant is a benign polymorphism found primarily in populations of East Asian origin. c.145A>C has been reported in the literature in a Chinese family in three individuals affected with Primary Hyperoxaluria Type 1, however all three affected family members carried a truncating variant in cis with the variant of interest (Wang_2016). Therefore, this report does not provide unequivocal conclusions about association of the variant with Primary Hyperoxaluria Type 1. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and classified the variant as benign, likely benign or uncertain significance. Based on the evidence outlined above, the variant was classified as benign. - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at